Cannabics Pharmaceuticals Inc announced it has begun a scientific collaboration with a medical laboratory in Europe, a world leader in the field of CTC count and drug sensitivity tests for cancer patients.
The company wishes to provide patients with information regarding the effectiveness of both cannabinoid compounds and other therapies. The blood test results enables practitioners and patients to monitor the number of circulating tumor cells as an indication for cancer characteristics, treatment efficacy and and re-occurrence.
Dr. Eyal Ballan, Co-founder and CTO, said: “Many cancer patients are treated with cannabis, either in conjunction with chemotherapy or without. Our aim is to provide them with a lab test to help monitor the effectiveness of the treatment, using a simple blood test.”
For further information, please contact:
Cannabics Pharmaceuticals, Inc.
Co- founder & CEO
Cannabics Pharmaceuticals Inc.